Happy to share a recent publication to kick off bleeding disorders awareness month! mdpi.com/2077-0383/15/4/1517…

In a recent interview, @JonRob08 of @BloodExpertsIL discusses the findings of a study evaluating joint health status & bleeding phenotype in patients with severe & non-severe #hemophilia A or B using musculoskeletal ultrasound and other clinical tools.🩸 Watch here: 👉 ow.ly/YRzs50XLmKr #Hematology #ASH25

Interesting news and was really only a matter of time. Companies should listen to patients, and each individual weigh risks/benefits of all evolving hemophilia therapies. Sometimes patience is the wise approach. #hemophilia #genetherapy reuters.com/business/healthc…

Honored to receive the Mary Draeger Schultz scholarship 2024 @OSFHealthCare! Grateful for the opportunity to promote #QI and #PatientSafety in healthcare, and for the incredible support from @UICOMPeoria @UicompP

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and VWD. onlinelibrary.wiley.com/doi/… This article developed by a global team of 48 experts and international organizations rigorously examines a number of GRADE methodology adaptations.

Come say Hi! 🍷 Poster number: 5014 x.com/docrishabhsingh/status…

A critique of the ISTH Haemophilia Guidelines was published in #Haemophilia Journal today with 49 eminent authors representing a global mixture of expertise, all united in their serious concerns about these guidelines which were already outdated on publication 1/3

Here is our just published review in #Blood focusing on how new biological insights into #FVIII are setting the stage for new #hemophilia therapies. #hemesky #medsky authors.elsevier.com/a/1k8Qn…

With 70% of bleeding events linked to identified or suspected causes, this study highlights the pressing need for better strategies, including long-term VWD factor (VWF) prophylaxis, to reduce hospitalizations and improve quality of life. Read More: bit.ly/3UWiu6Z

Centessa have discontinued development of their rebalancing agent, Serpin PC despite encouraging Phase 2 PREScent clinical trial results Decision due to competition from marstacimab and possibly concizumab. This leaves these 2 plus Fitusiran in trials or licenced @ProfMakris

I strongly disagree with this commentary in the journal Blood Transfusion. The authors try to justify the decision of the @WHO to have cryoprecipitate and pathogen reduced cryoprecipitate (rather than FVIII concentrate) for the treatment of #hemophilia in the list of essential medicines. I do not know of ANY hemophilia treater who agrees with the World Health Organisation policy. What they recommend is dangerous for persons with #hemophilia in poor countries. Pathogen reduced cryo is only available in a tiny number of countries (?2). So essentially they are recommending unsafe cryoprecipitate and suggesting these poor countries introduce the technology to pathogen reduce the cryoprecipitate. It is about time that the @WHO includes hemophilia treaters in the "expert panel" who make recommendations for treatment of persons with hemophilia. tinyurl.com/mtuyt5fs

Congratulations Dr @leslieskeith!! Amazing work.